Search

Displaying results 2521 - 2530 of 8010 in total
  1. Drug

    Tamoxifen

    go.drugbank.com/drugs/DB00675
    ApprovedInvestigational

    [L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.

  2. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … [A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting

  3. Drug

    Alprazolam

    go.drugbank.com/drugs/DB00404
    ApprovedIllicitInvestigational

    Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. … [L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.

    Products: ALPRAZOLAM MK 0.5 MG TABLETAS, ALPRAZOLAM MK 0.25 MG TABLETAS
  4. Drug

    Sulindac

    go.drugbank.com/drugs/DB00605
    ApprovedInvestigational

    There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. … Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes.

  5. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.

  6. Drug

    Triethylenetetramine

    go.drugbank.com/drugs/DB06824
    ApprovedInvestigational

    [A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … [L41730] TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335]

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    cell morphology and a risk for transformation to acute myeloid leukemia. … [A187838] Standard therapy for anemia in patients with MDS involves the use of erythropoiesis-stimulating agents (e.g.

  8. Drug

    Trazodone

    go.drugbank.com/drugs/DB00656
    ApprovedInvestigational

    Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. … [T646] Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters

    Categories: Antidepressive Agents Indicated for Depression
  9. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

  10. Drug

    Choline magnesium trisalicylate

    go.drugbank.com/drugs/DB01401
    Approved

    Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [A19653, A19654].